Business Description
Minapharm Pharmaceuticals
ISIN : EGS380G1C011
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.51 | |||||
Equity-to-Asset | 0.39 | |||||
Debt-to-Equity | 1.1 | |||||
Debt-to-EBITDA | 7.88 | |||||
Interest Coverage | 1.22 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 0.45 | |||||
9-Day RSI | 0.7 | |||||
14-Day RSI | 1.68 | |||||
6-1 Month Momentum % | -30.7 | |||||
12-1 Month Momentum % | -9.52 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.14 | |||||
Quick Ratio | 0.85 | |||||
Cash Ratio | 0.54 | |||||
Days Inventory | 130.86 | |||||
Days Sales Outstanding | 45.53 | |||||
Days Payable | 98.9 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.01 | |||||
Forward Dividend Yield % | 1.01 | |||||
5-Year Yield-on-Cost % | 1.01 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 32.16 | |||||
Operating Margin % | 7.99 | |||||
Net Margin % | -0.82 | |||||
FCF Margin % | -33.48 | |||||
ROE % | -1 | |||||
ROA % | -0.41 | |||||
ROIC % | 3.52 | |||||
ROC (Joel Greenblatt) % | 7.13 | |||||
ROCE % | 6.07 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.47 | |||||
PB Ratio | 0.58 | |||||
Price-to-Tangible-Book | 0.67 | |||||
Price-to-Operating-Cash-Flow | 17.16 | |||||
EV-to-EBIT | 13.49 | |||||
EV-to-EBITDA | 8.08 | |||||
EV-to-Revenue | 1 | |||||
EV-to-FCF | -3.03 | |||||
Earnings Yield (Greenblatt) % | 7.41 | |||||
FCF Yield % | -64.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Minapharm Pharmaceuticals Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil E£) | 3,892.05 | ||
EPS (TTM) (E£) | -5 | ||
Beta | 0 | ||
Volatility % | 36.91 | ||
14-Day RSI | 1.68 | ||
14-Day ATR (E£) | 4.680054 | ||
20-Day SMA (E£) | 172.359 | ||
12-1 Month Momentum % | -9.52 | ||
52-Week Range (E£) | 163 - 294.7 | ||
Shares Outstanding (Mil) | 12.29 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Minapharm Pharmaceuticals Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Minapharm Pharmaceuticals Stock Events
Event | Date | Price(E£) | ||
---|---|---|---|---|
No Event Data |
Minapharm Pharmaceuticals Frequently Asked Questions
What is Minapharm Pharmaceuticals(CAI:MIPH)'s stock price today?
When is next earnings date of Minapharm Pharmaceuticals(CAI:MIPH)?
Does Minapharm Pharmaceuticals(CAI:MIPH) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |